Global Meningococcal Vaccines Market - Snapshot

The global meningococcal vaccines market was valued at approximately US$ 3.3 Bn in 2017 and is anticipated to reach a value of approximately US$ 9.9 Bn by 2026, expanding at a CAGR of 12.9% from 2018 to 2026. The global meningococcal vaccines market is driven by favorable public-private partnerships to support development of vaccines at low cost and the medical emergency status of the disease. Increase in demand for vaccines and the number of people getting immunized has majorly contributed to education and awareness campaigns conducted by manufacturers as well as non-profit organizations in developed countries. Government intervention, such as approval of legislations to mandate immunization programs for school children up to a certain age, and stringent regulations for Hajj pilgrims and sub-Saharan travelers also drive the market due to increased demand for these vaccines from non-profit organizations. 

The global meningococcal vaccines market has been segmented based on type, end-user, and region. In terms of type, the global market has been classified into polysaccharide vaccines, conjugate vaccines, combination vaccines, and Men B vaccines. The polysaccharide vaccines segment has been further sub-segmented into Menomune, Mencevax, NmVac4, and others. The conjugate vaccines segment has been further sub-segmented into Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, Menjugate, MenAfriVac, and NmVac4-DT. The combination vaccines segment has been further split into MenHibrix and Menitorix. The Men B vaccines segment has been further sub-segmented into Bexsero and Trumenba. Based on end-user, the market has been classified into retail pharmacies, hospital pharmacies, and others. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

global meningococcal vaccines market

In terms of type, the conjugate vaccines segment is anticipated to dominate the global meningococcal vaccines market, owing to high usage of conjugate meningococcal vaccines, which are known to be superior to polysaccharide vaccines due to their ability to elicit greater and long lasting immunity, facilitation of immunologic memory, and protection to infants. 

In terms of region, North America was a prominent market, globally, in terms of revenue, in 2017. In North America and Europe, due to government intervention with respect to legislations, immunization programs and awareness campaigns, incidences of meningitis have reduced significantly. According to a report by the U.S. Centers for Disease Control and Prevention (CDC), 1,000 to 2,600 people contract meningococcal disease each year in the U.S., while in Africa, it is estimated to be 1,000 cases per 100,000 population. The market in Asia Pacific is expected to expand at a rapid pace, followed by the market in Rest of the World (RoW). during the forecast period. Factors driving the market in Asia Pacific include continuous rise in population base, cyclic occurrences of meningococcal disease outbreaks in the past, and increased focus on preventive measures against the dreadful diseases. The onset of recent trends such as enrolment of pharmacists in training programs, conducted by New Zealand Ministry of Health, is also boosting the market. 

Major players operating in the global meningococcal vaccines market include Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. Increase in mergers & acquisitions, new product development, and strategic collaborations between major companies and governing authorities are expected to drive the global market during the forecast period.

Global Meningococcal Vaccines Market: Overview

This report analyzes the current and future scenario of the global meningococcal vaccines market. Advancements in healthcare, increase in awareness and education through various non-profit organizations, and a rise in patient awareness and health care expenditure are key factors that are projected to drive the global market during the forecast period. 

The global meningococcal vaccines market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises a competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market. 

Global Meningococcal vaccines Market: Key Segments

The global meningococcal vaccines market has been segmented based on type, end-user, and region. In terms of type, the global market has been classified into polysaccharide vaccines, conjugate vaccines, combination vaccines, and Men B vaccines. The polysaccharide vaccines segment has been further sub-segmented into Menomune, Mencevax, NmVac4, and others. The conjugate vaccines segment has been further sub-segmented into Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, Menjugate, MenAfriVac, and NmVac4-DT. The combination vaccines segment has been further split into MenHibrix, and Menitorix. The Men B vaccines segment has been further sub-segmented into Bexsero, and Trumenba. Based on end-user, the market has been classified into retail pharmacies, hospital pharmacies, and others. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Meningococcal vaccines Market: Regional Outlook

In terms of region, the global meningococcal vaccines market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in the Report

The report also profiles major players in the global meningococcal vaccines market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. 

The global meningococcal vaccines market has been segmented as below:

Type

  • Polysaccharide Vaccines
    • Menomune
    • Mencevax
    • NmVac4
    • Others
  • Conjugate Vaccines
    • Menactra
    • Menveo
    • NeisVac-C
    • Nimenrix
    • Meningitec
    • Menjugate
    • MenAfriVac
    • NmVac4-DT
  • Combination Vaccines
    • MenHibrix
    • Menitorix
  • Men B Vaccines
    • Bexsero
    • Trumenba

End-user

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others 

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

 

End-use Industry

  • Aerospace & Defense
  • Automotive
  • Consumer Electronics
  • Healthcare
  • Food & Beverages
  • Energy & Utility
  • Others (Including Telecommunication, Photonics, and Manufacturing)

Region

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • U.K.
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Meningococcal Vaccines Market

Buy Now